EP2971288A4 - Compositions, methods, and computer systems related to making and administering modified t cells - Google Patents

Compositions, methods, and computer systems related to making and administering modified t cells

Info

Publication number
EP2971288A4
EP2971288A4 EP14773595.5A EP14773595A EP2971288A4 EP 2971288 A4 EP2971288 A4 EP 2971288A4 EP 14773595 A EP14773595 A EP 14773595A EP 2971288 A4 EP2971288 A4 EP 2971288A4
Authority
EP
European Patent Office
Prior art keywords
compositions
cells
making
methods
computer systems
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP14773595.5A
Other languages
German (de)
French (fr)
Other versions
EP2971288A1 (en
Inventor
Roderick A Hyde
Wayne R Kindsvogel
Gary L Mcknight
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elwha LLC
Original Assignee
Elwha LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/827,960 external-priority patent/US9499855B2/en
Priority claimed from US13/804,224 external-priority patent/US9587237B2/en
Priority claimed from US13/826,803 external-priority patent/US20140274801A1/en
Application filed by Elwha LLC filed Critical Elwha LLC
Publication of EP2971288A1 publication Critical patent/EP2971288A1/en
Publication of EP2971288A4 publication Critical patent/EP2971288A4/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464403—Receptors for growth factors
    • A61K39/464404—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464403—Receptors for growth factors
    • A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464469—Tumor associated carbohydrates
    • A61K39/46447—Mucins, e.g. MUC-1
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/30—Detection of binding sites or motifs
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by targeting or presenting multiple antigens
    • A61K2239/29—Multispecific CARs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/49—Breast
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
EP14773595.5A 2013-03-14 2014-03-11 Compositions, methods, and computer systems related to making and administering modified t cells Ceased EP2971288A4 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13/827,960 US9499855B2 (en) 2013-03-14 2013-03-14 Compositions, methods, and computer systems related to making and administering modified T cells
US13/804,224 US9587237B2 (en) 2013-03-14 2013-03-14 Compositions, methods, and computer systems related to making and administering modified T cells
US13/826,803 US20140274801A1 (en) 2013-03-14 2013-03-14 Compositions, methods, and computer systems related to making and administering modified t cells
PCT/US2014/023650 WO2014159435A1 (en) 2013-03-14 2014-03-11 Compositions, methods, and computer systems related to making and administering modified t cells

Publications (2)

Publication Number Publication Date
EP2971288A1 EP2971288A1 (en) 2016-01-20
EP2971288A4 true EP2971288A4 (en) 2016-12-07

Family

ID=51625167

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14773595.5A Ceased EP2971288A4 (en) 2013-03-14 2014-03-11 Compositions, methods, and computer systems related to making and administering modified t cells

Country Status (2)

Country Link
EP (1) EP2971288A4 (en)
WO (1) WO2014159435A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2752933C2 (en) 2014-03-11 2021-08-11 Селлектис Method for creation of t-cells suitable for allogeneic transplantation
CN105985444B (en) * 2015-02-05 2024-02-13 博生吉安科细胞技术有限公司 Chimeric antigen receptor, and method and application for rapidly constructing chimeric antigen receptor
US20170224796A1 (en) 2016-02-05 2017-08-10 Xeme Biopharma Inc. Therapeutic Cancer Vaccine Containing Tumor-Associated Neoantigens and Immunostimulants in a Delivery System
KR20210148293A (en) 2019-04-03 2021-12-07 프리시젼 바이오사이언시스 인코포레이티드 Gene-modified immune cells containing microRNA-adapted shRNAs (shRNAmiRs)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5601819A (en) * 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US20070036773A1 (en) * 2005-08-09 2007-02-15 City Of Hope Generation and application of universal T cells for B-ALL

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1118661A1 (en) * 2000-01-13 2001-07-25 Het Nederlands Kanker Instituut T cell receptor libraries
US20050026199A1 (en) * 2000-01-21 2005-02-03 Shaw Sandy C. Method for identifying biomarkers using Fractal Genomics Modeling
CA2440474A1 (en) * 2001-04-05 2002-10-17 Virginia Mason Research Center Methods of mhc class ii epitope mapping, detection of autoimmune t cells and antigens, and autoimmune treatment
AT503861B1 (en) * 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw METHOD FOR MANIPULATING T-CELL RECEPTORS
CA2666320A1 (en) * 2006-10-11 2008-04-17 Antitope Limited T cell epitope databases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5601819A (en) * 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US20070036773A1 (en) * 2005-08-09 2007-02-15 City Of Hope Generation and application of universal T cells for B-ALL

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CAMERON J TURTLE ET AL: "Engineered T cells for anti-cancer therapy", CURRENT OPINION IN IMMUNOLOGY., vol. 24, no. 5, 18 July 2012 (2012-07-18), GB, pages 633 - 639, XP055272888, ISSN: 0952-7915, DOI: 10.1016/j.coi.2012.06.004 *
CHRISTOPHER C KLOSS ET AL: "Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells", NATURE BIOTECHNOLOGY, vol. 31, no. 1, 16 December 2012 (2012-12-16), pages 71 - 75, XP055130697, ISSN: 1087-0156, DOI: 10.1038/nbt.2459 *
KEN-ICHI HANADA ET AL: "nature biotechnology volume 31 number 1 JAnuArY 2013 33", 1 January 2013 (2013-01-01), XP055290041, Retrieved from the Internet <URL:http://www.nature.com/nbt/journal/v31/n1/pdf/nbt.2471.pdf> [retrieved on 20160720] *
SCOTT WILKIE ET AL: "Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling", JOURNAL OF CLINICAL IMMUNOLOGY, KLUWER ACADEMIC PUBLISHERS-PLENUM PUBLISHERS, NE, vol. 32, no. 5, 17 April 2012 (2012-04-17), pages 1059 - 1070, XP035113362, ISSN: 1573-2592, DOI: 10.1007/S10875-012-9689-9 *
See also references of WO2014159435A1 *
UTTENTHAL BENJAMIN J ET AL: "Challenges in T cell receptor gene therapy.", THE JOURNAL OF GENE MEDICINE JUN 2012, vol. 14, no. 6, June 2012 (2012-06-01), pages 386 - 399, XP002760096, ISSN: 1521-2254 *

Also Published As

Publication number Publication date
EP2971288A1 (en) 2016-01-20
WO2014159435A1 (en) 2014-10-02

Similar Documents

Publication Publication Date Title
IL272324B (en) Methods, systems and compositions relating to cell conversion via protein induced in-vivo cell reprogramming
IL269461B (en) Cytidine-5-carboxamide modified nucleotide compositions and methods related thereto
HK1222741A1 (en) Improved fuel cell systems and methods
PT3066201T (en) Crispr-related methods and compositions with governing grnas
EP3063545A4 (en) Systems and methods for processing data relating to energy usage
EP3055793A4 (en) Systems and methods for adding descriptive metadata to digital content
SG11201602278YA (en) Virtual computing systems and methods
EP2970909A4 (en) Methods and compositions related to t-cell activity
EP2943591A4 (en) Methods and compositions for single cell expression profiling
GB201322094D0 (en) Methods and compositions relating to alzheimers disease
IL245524A0 (en) New methods to produce active tert
EP2971030B8 (en) Oligosaccharide compositions, glycoproteins and methods to produce the same in prokaryotes
EP2988764A4 (en) Anti-dandruff compositions, and methods of use thereof
SG11201510209SA (en) Cell populations, methods of transdifferention and methods of use thereof
EP2964610A4 (en) Vinylsulfone-based 18f-labeling compositions and methods and uses thereof
SG10201914005TA (en) Methods and compositions for producing hepatocyte-like cells
PT3066199T (en) Snorna, compositions and uses
EP2971288A4 (en) Compositions, methods, and computer systems related to making and administering modified t cells
HK1213810A1 (en) Nsaid administration and related compositions, methods and systems nsaid
EP3011336A4 (en) Methods, systems, and composition related to neural disorders
EP3050265A4 (en) Content distribution using social relationships
EP2992031A4 (en) Aliphatic polycarbonate compositions and methods
GB201319917D0 (en) Accelerator Compositions and Methods
AU2013903254A0 (en) Probiotic compositions and uses thereof (IV)

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20151014

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: G06F 19/00 20110101ALI20160722BHEP

Ipc: C40B 40/02 20060101AFI20160722BHEP

Ipc: C12N 5/0783 20100101ALI20160722BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20161108

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 5/0783 20100101ALI20161102BHEP

Ipc: C40B 40/02 20060101AFI20161102BHEP

Ipc: G06F 19/00 20110101ALI20161102BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20170928

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20190606